Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 14/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 14/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 1.00 |
| ▸ | PARP1 | P09874 | 8/20 | 0.80 |
| ▸ | GUSB | P08236 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165829 | 0.89 | TNKS (1.00) | TNKSTNKS2PARP2PARP1 | |
| SCHEMBL7568249 | 0.89 | TNKS (1.00) | TNKSTNKS2PARP2PARP1GUSB | |
| SCHEMBL15775361 | 0.89 | TNKS (1.00) | TNKSTNKS2PARP2PARP1 | |
| SCHEMBL15775274 | 0.88 | TNKS (1.00) | TNKSTNKS2PARP2PARP1 | |
| SCHEMBL15775173 | 0.88 | TNKS (1.00) | TNKSTNKS2PARP2PARP1GUSB | |
| SCHEMBL11102850 | 0.88 | TNKS (0.79) | TNKSTNKS2PARP2PARP1GUSB | |
| SCHEMBL15775410 | 0.88 | TNKS (1.00) | TNKSTNKS2PARP2PARP1 | |
| Hydrochloric Acid SCHEMBL28060794 | 0.88 | TNKS (0.97) | TNKSTNKS2PARP2PARP1 | |
| SCHEMBL15775435 | 0.85 | TNKS (0.74) | TNKSTNKS2PARP2PARP1GUSB | |
| SCHEMBL7570159 | 0.84 | TNKS (0.73) | TNKSTNKS2PARP2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0897915-B1 | Quinazolinone compounds as chemotherapeutic agents | UNIV NEWCASTLE VENTURES LTD (GB) | 2003-01-22 | — | — | EP | claimed |
| EP-0897915-A1 | QUINAZOLINONE CONPOUNDS AS CHEMOTHERAPEUTIC AGENTS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1999-02-24 | — | — | EP | claimed |
| JP-H09510704-A | — | — | 1997-10-28 | — | — | JP | claimed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | claimed |
| WO-2014087165-A1 | TANKYRASE INHIBITORS | UNIVERSITY OF BATH (GB) | 2014-06-12 | — | — | WO | disclosed |
| EP-0897915-B1 | Quinazolinone compounds as chemotherapeutic agents | UNIV NEWCASTLE VENTURES LTD (GB) | 2003-01-22 | — | — | EP | disclosed |
| EP-0966476-B1 | Quinazolinone compounds | UNIV NEWCASTLE VENTURES LTD (GB) | 2002-09-04 | — | — | EP | disclosed |
| US-6348475-B1 | POLYMERASE INHIBITOR | GUILFORD PHARMACEUTICALS INC. | 2002-02-19 | — | — | US | disclosed |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | EISAI INC. | 2002-02-14 | — | — | US | disclosed |
| US-6316455-B1 | Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-11-13 | — | — | US | disclosed |
| US-6015827-A | Benzoxazole-4-carboxamides and their use in inhibiting poly (adp-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy | NEWCASTLE UNIVERSITY VENTURES LIMITED | 2000-01-18 | — | — | US | disclosed |
| EP-0966476-A1 | QUINAZOLINONE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| EP-0897915-A1 | QUINAZOLINONE CONPOUNDS AS CHEMOTHERAPEUTIC AGENTS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1999-02-24 | — | — | EP | disclosed |
| WO-1998033802-A1 | QUINAZOLINONE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-08-06 | — | — | WO | disclosed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | PARP2, PARP1, PARP3 | TNKS 22/4885TNKS2 39/4885PARP2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.